CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer
Author:
Xu Haineng,
Gitto Sarah B.ORCID,
Ho Gwo-Yaw,
Medvedev Sergey,
Shield-Artin Kristy,
Kim Hyoung,
Beard Sally,
Kinose Yasuto,
Wang Xiaolei,
Barker Holly E.,
Ratnayake Gayanie,
Hwang Wei-Ting,
Hansen Ryan J.,
Strouse Bryan,
Milutinovic Snezana,
Hassig Christian,
Wakefield Matthew J.,
Vandenberg Cassandra J.,
Scott Clare L.,
Simpkins FionaORCID